MedicaidPrior AuthMedium impact
Monjuvi® (tafasitamab-cxix) (New)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Oct 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has established a new prior authorization policy for Monjuvi® (tafasitamab-cxix), an IV cancer medication used to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma. This medication requires prior authorization with specific clinical criteria including combination therapy requirements and treatment duration limits.
Action Required
Before October 1, 2025: Billing and clinical teams must establish prior authorization workflows for Monjuvi® (tafasitamab-cxix) for Louisiana Medicaid patients. Update EMR templates to capture required clinical criteria including DLBCL/follicular lymphoma diagnosis, relapsed/refractory disease status, autologous stem cell transplant eligibility, and combination therapy plans. Train staff to obtain prior authorization before administering this medication as claims will be denied without approval.